Ikena Oncology Inc (IKNA) - Net Assets
Based on the latest financial reports, Ikena Oncology Inc (IKNA) has net assets worth $115.91 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($126.17 Million) and total liabilities ($10.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Ikena Oncology Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $115.91 Million |
| % of Total Assets | 91.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.35 |
Ikena Oncology Inc - Net Assets Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Ikena Oncology Inc for the complete picture of this company's asset base.
Annual Net Assets for Ikena Oncology Inc (2018–2024)
The table below shows the annual net assets of Ikena Oncology Inc from 2018 to 2024. For live valuation and market cap data, see market cap of Ikena Oncology Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $125.93 Million | -25.82% |
| 2023-12-31 | $169.76 Million | +15.51% |
| 2022-12-31 | $146.97 Million | -29.30% |
| 2021-12-31 | $207.88 Million | +305.72% |
| 2020-12-31 | $-101.05 Million | -64.40% |
| 2019-12-31 | $-61.46 Million | -34.08% |
| 2018-12-31 | $-45.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ikena Oncology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28135300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.04% |
| Other Comprehensive Income | $68.00K | 0.05% |
| Other Components | $457.44 Million | 363.24% |
| Total Equity | $125.93 Million | 100.00% |
Ikena Oncology Inc Competitors by Market Cap
The table below lists competitors of Ikena Oncology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Titania Holding AB Series B
ST:TITA-B
|
$59.92 Million |
|
Luo Lih Fen Holding Co Ltd
TW:6666
|
$59.94 Million |
|
JKG Land Bhd
KLSE:6769
|
$59.97 Million |
|
A-Tech Solution Co. Ltd
KQ:071670
|
$59.98 Million |
|
Infragreen Group Ltd
AU:IFN
|
$59.90 Million |
|
Professional Computer Technology Ltd
TWO:6270
|
$59.89 Million |
|
Taiwan Ostor
TWO:8080
|
$59.88 Million |
|
Kuangli Photoelectric Technology Co Ltd
TW:6431
|
$59.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ikena Oncology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 169,757,000 to 125,934,000, a change of -43,823,000 (-25.8%).
- Net loss of 49,234,000 reduced equity.
- Other comprehensive income increased equity by 116,000.
- Other factors increased equity by 5,295,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.23 Million | -39.1% |
| Other Comprehensive Income | $116.00K | +0.09% |
| Other Changes | $5.29 Million | +4.2% |
| Total Change | $- | -25.82% |
Book Value vs Market Value Analysis
This analysis compares Ikena Oncology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.28 | $1.43 | x |
| 2019-12-31 | $0.49 | $1.43 | x |
| 2020-12-31 | $-2.82 | $1.43 | x |
| 2021-12-31 | $5.78 | $1.43 | x |
| 2022-12-31 | $4.06 | $1.43 | x |
| 2023-12-31 | $4.07 | $1.43 | x |
| 2024-12-31 | $2.61 | $1.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ikena Oncology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-39.10%) is below the historical average (-34.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -4127.78% | 0.05x | 0.00x | $-36.28 Million |
| 2019 | -96.63% | -122.28% | 0.16x | 4.94x | $-18.56 Million |
| 2020 | 0.00% | -481.36% | 0.05x | 0.00x | $-34.15 Million |
| 2021 | -16.41% | -110.10% | 0.13x | 1.19x | $-54.90 Million |
| 2022 | -46.79% | -440.29% | 0.09x | 1.17x | $-83.46 Million |
| 2023 | -40.16% | -744.17% | 0.05x | 1.13x | $-85.14 Million |
| 2024 | -39.10% | 0.00% | 0.00x | 1.12x | $-61.83 Million |
Industry Comparison
This section compares Ikena Oncology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ikena Oncology Inc (IKNA) | $115.91 Million | 0.00% | 0.09x | $59.90 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more